Log in to your Inderes Free account to see all free content on this page.
Create account

Aiforia Technologies

2.16 EUR

-2.05 %

2,196 following
Corporate customer

AIFORIA

First North Finland

Medical Equipment & Services

Health Care

-2.05 %
+24.57 %
+4.11 %
-13.45 %
-12.04 %
-38.43 %
-46.13 %
-
-57.41 %

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more
Market cap
72.81M EUR
Turnover
222.83K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
09.03.2026
Disclaimer
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 09.03.2026

Latest extensive report

Released: 24.04.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
28.8.
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
Greetings from the EGM. In a brief opening speech, the Chair of the Board stated that Aiforia is in an excellent position. The Board’s proposal was approved, with 99.98% of the votes in favor. One shareholder asked a few questions, mainly regarding whether there were alternatives...
18 hours ago
by Puutaheinää
35
Tämä on kolmannen osapuolen analyysi, eikä välttämättä vastaa Inderesin näkemystä tai arvoja. Inderes Aiforia Technologies: Strong cross-read from Roche's PathAI takeover - NuWays... Last week, Roche announced the acquisition of PathAI for up to $ 1.05bn ($ 750m upfront, $ 300m in...
yesterday
by TO
17
It’s easy to get excited about these M&A deals, and for good reason. After all, it’s potentially a way to get your money back from “Hesuli” (Helsinki Stock Exchange) micro-caps, whose price development is steadily heading south (northeast in sarcasm). However, they actually happen...
yesterday
by Opa
12
Here is Roche’s own press release regarding the PathAI acquisition, detailing the rationale behind what they wanted to buy and why. The arguments could be copied if someone wanted to acquire Aiforia. However, even though peers for Bittium’s medical business, for example, were sold...
yesterday
by Opa
8
Some big fish will surely buy this at some point, but probably not just yet, as insiders have only recently been buying. In my opinion, it would also be better to develop the company further and get more references and AI models → better valuation. I’d also rather keep this on the...
5/8/2026, 7:42 PM
by Jekkku
6
At the extraordinary general meeting (EGM) on Tuesday, May 12, the board will be authorized to carry out a share issue of a maximum of 5 million shares. At the current share price, the subscription price would likely be around €1.7–1.8 per share, and the total number of shares would...
5/8/2026, 5:01 PM
by Jekkku
6
Well, the shareholder base itself is partly problematic here, as they blocked a share issue that was essential for the growth story.
5/8/2026, 8:34 PM
by Puutaheinää
5
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.